60 Degrees Pharma Q3 net product revenue rises

60 Degrees Pharmaceuticals

13/11/2025 19:00

Overview

60 Degrees Pharmaceuticals Q3 net product revenue up 223% yr/yr to $438 thousand

Company reports Q3 gross loss of $100 thousand due to inventory write-off

Operating expenses rose to $2.32 mln in Q3, driven by higher advertising costs

Outlook

Company did not provide specific financial guidance for future quarters or full year

Result Drivers

INVENTORY WRITE-OFF - Gross loss attributed to a one-time inventory write-off for validation lots with limited shelf-life

HIGHER ADVERTISING COSTS - Increase in operating expenses driven by $367 thousand in additional advertising and sales promotion expenditures

ARAKODA® DELIVERIES - ARAKODA® pharmacy deliveries increased by 14% from 1,319 boxes (Q3 2024) to 1,505 boxes (Q3 2025)

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q3 EPS
-$0.66
Q3 Net Income
-$2.44 mln
Q3 Operating Expenses
$2.32 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 1 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"

Wall Street's median 12-month price target for 60 Degrees Pharmaceuticals Inc is $7.00, about 82.4% above its November 12 closing price of $1.23

Press Release: ID:nGNX7c7M5s

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)